Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Type of vascular invasion in association with progress of endometrial cancer.

Visser NCM, Werner HMJ, Krakstad C, Mauland KK, Trovik J, Massuger LFAG, Nagtegaal ID, Pijnenborg JMA, Salvesen HB, Bulten J, Stefansson IM.

APMIS. 2017 Dec;125(12):1084-1091. doi: 10.1111/apm.12774. Epub 2017 Oct 4.

PMID:
28975668
2.

In vivo MR spectroscopy predicts high tumor grade in endometrial cancer.

Ytre-Hauge S, Esmaeili M, Sjøbakk TE, Grüner R, Woie K, Werner HM, Krakstad C, Bjørge L, Salvesen ØO, Stefansson IM, Trovik J, Bathen TF, Haldorsen IS.

Acta Radiol. 2018 Apr;59(4):497-505. doi: 10.1177/0284185117733297. Epub 2017 Sep 19.

PMID:
28927296
3.

Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer.

Krüger K, Wik E, Knutsvik G, Nalwoga H, Klingen TA, Arnes JB, Chen Y, Mannelqvist M, Dimitrakopoulou K, Stefansson IM, Birkeland E, Aas T, Tobin NP, Jonassen I, Bergh J, Foulkes WD, Akslen LA.

Sci Rep. 2017 Apr 24;7(1):1089. doi: 10.1038/s41598-017-00862-w.

4.

Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival.

Mauland KK, Wik E, Hoivik EA, Kusonmano K, Halle MK, Berg A, Haugland HK, Øyan AM, Kalland KH, Stefansson IM, Akslen LA, Krakstad C, Trovik J, Werner HM, Salvesen HB.

Oncotarget. 2017 Feb 7;8(6):9696-9707. doi: 10.18632/oncotarget.14201.

5.

Tumour cell invasion into blood vessels is significantly related to breast cancer subtypes and decreased survival.

Klingen TA, Chen Y, Stefansson IM, Knutsvik G, Collett K, Abrahamsen AL, Aase H, Aas H, Aas T, Wik E, Akslen LA.

J Clin Pathol. 2017 Apr;70(4):313-319. doi: 10.1136/jclinpath-2016-203861. Epub 2016 Sep 9.

PMID:
27612505
6.

QSOX1 expression is associated with aggressive tumor features and reduced survival in breast carcinomas.

Knutsvik G, Collett K, Arnes J, Akslen LA, Stefansson IM.

Mod Pathol. 2016 Dec;29(12):1485-1491. doi: 10.1038/modpathol.2016.148. Epub 2016 Aug 26.

7.

The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis.

Gibson WJ, Hoivik EA, Halle MK, Taylor-Weiner A, Cherniack AD, Berg A, Holst F, Zack TI, Werner HM, Staby KM, Rosenberg M, Stefansson IM, Kusonmano K, Chevalier A, Mauland KK, Trovik J, Krakstad C, Giannakis M, Hodis E, Woie K, Bjorge L, Vintermyr OK, Wala JA, Lawrence MS, Getz G, Carter SL, Beroukhim R, Salvesen HB.

Nat Genet. 2016 Aug;48(8):848-55. doi: 10.1038/ng.3602. Epub 2016 Jun 27.

8.

Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses.

Bredholt G, Mannelqvist M, Stefansson IM, Birkeland E, Bø TH, Øyan AM, Trovik J, Kalland KH, Jonassen I, Salvesen HB, Wik E, Akslen LA.

Oncotarget. 2015 Nov 24;6(37):39676-91. doi: 10.18632/oncotarget.5344.

9.

Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer.

Stefansson IM, Raeder M, Wik E, Mannelqvist M, Kusonmano K, Knutsvik G, Haldorsen I, Trovik J, Øyan AM, Kalland KH, Staff AC, Salvesen HB, Akslen LA.

Oncotarget. 2015 Apr 30;6(12):10634-45.

10.

Preoperative tumor size at MRI predicts deep myometrial invasion, lymph node metastases, and patient outcome in endometrial carcinomas.

Ytre-Hauge S, Husby JA, Magnussen IJ, Werner HM, Salvesen ØO, Bjørge L, Trovik J, Stefansson IM, Salvesen HB, Haldorsen IS.

Int J Gynecol Cancer. 2015 Mar;25(3):459-66. doi: 10.1097/IGC.0000000000000367.

11.

Evaluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarrays.

Knutsvik G, Stefansson IM, Aziz S, Arnes J, Eide J, Collett K, Akslen LA.

PLoS One. 2014 Nov 6;9(11):e112121. doi: 10.1371/journal.pone.0112121. eCollection 2014.

12.

Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations.

Wik E, Trovik J, Kusonmano K, Birkeland E, Raeder MB, Pashtan I, Hoivik EA, Krakstad C, Werner HM, Holst F, Mjøs S, Halle MK, Mannelqvist M, Mauland KK, Oyan AM, Stefansson IM, Petersen K, Simon R, Cherniack AD, Meyerson M, Kalland KH, Akslen LA, Salvesen HB.

Gynecol Oncol. 2014 Sep;134(3):599-606. doi: 10.1016/j.ygyno.2014.06.026. Epub 2014 Jul 1.

PMID:
24995579
13.

An 18-gene signature for vascular invasion is associated with aggressive features and reduced survival in breast cancer.

Mannelqvist M, Wik E, Stefansson IM, Akslen LA.

PLoS One. 2014 Jun 6;9(6):e98787. doi: 10.1371/journal.pone.0098787. eCollection 2014.

14.

Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial.

Trovik J, Wik E, Werner HM, Krakstad C, Helland H, Vandenput I, Njolstad TS, Stefansson IM, Marcickiewicz J, Tingulstad S, Staff AC; MoMaTEC study group, Amant F, Akslen LA, Salvesen HB.

Eur J Cancer. 2013 Nov;49(16):3431-41. doi: 10.1016/j.ejca.2013.06.016. Epub 2013 Aug 8.

15.

Expression of thyroid transcription factor-1 is associated with a basal-like phenotype in breast carcinomas.

Klingen TA, Chen Y, Suhrke P, Stefansson IM, Gundersen MD, Akslen LA.

Diagn Pathol. 2013 May 15;8:80. doi: 10.1186/1746-1596-8-80.

16.

High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition.

Wik E, Birkeland E, Trovik J, Werner HM, Hoivik EA, Mjos S, Krakstad C, Kusonmano K, Mauland K, Stefansson IM, Holst F, Petersen K, Oyan AM, Simon R, Kalland KH, Ricketts W, Akslen LA, Salvesen HB.

Clin Cancer Res. 2013 May 1;19(9):2331-41. doi: 10.1158/1078-0432.CCR-12-3413. Epub 2013 Mar 28.

17.

Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers.

Raeder MB, Birkeland E, Trovik J, Krakstad C, Shehata S, Schumacher S, Zack TI, Krohn A, Werner HM, Moody SE, Wik E, Stefansson IM, Holst F, Oyan AM, Tamayo P, Mesirov JP, Kalland KH, Akslen LA, Simon R, Beroukhim R, Salvesen HB.

PLoS One. 2013;8(2):e54873. doi: 10.1371/journal.pone.0054873. Epub 2013 Feb 5.

18.

Lack of estrogen receptor-α is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma.

Wik E, Ræder MB, Krakstad C, Trovik J, Birkeland E, Hoivik EA, Mjos S, Werner HM, Mannelqvist M, Stefansson IM, Oyan AM, Kalland KH, Akslen LA, Salvesen HB.

Clin Cancer Res. 2013 Mar 1;19(5):1094-105. doi: 10.1158/1078-0432.CCR-12-3039. Epub 2013 Jan 14.

19.

Microvessel proliferation by co-expression of endothelial nestin and Ki-67 is associated with a basal-like phenotype and aggressive features in breast cancer.

Krüger K, Stefansson IM, Collett K, Arnes JB, Aas T, Akslen LA.

Breast. 2013 Jun;22(3):282-8. doi: 10.1016/j.breast.2012.07.008. Epub 2012 Jul 26.

20.

Lipocalin 2 expression is associated with aggressive features of endometrial cancer.

Mannelqvist M, Stefansson IM, Wik E, Kusonmano K, Raeder MB, Øyan AM, Kalland KH, Moses MA, Salvesen HB, Akslen LA.

BMC Cancer. 2012 May 6;12:169. doi: 10.1186/1471-2407-12-169.

21.

Loss of GPER identifies new targets for therapy among a subgroup of ERα-positive endometrial cancer patients with poor outcome.

Krakstad C, Trovik J, Wik E, Engelsen IB, Werner HM, Birkeland E, Raeder MB, Øyan AM, Stefansson IM, Kalland KH, Akslen LA, Salvesen HB.

Br J Cancer. 2012 May 8;106(10):1682-8. doi: 10.1038/bjc.2012.91. Epub 2012 Mar 13.

22.

Vascular proliferation is a prognostic factor in breast cancer.

Arnes JB, Stefansson IM, Straume O, Baak JP, Lønning PE, Foulkes WD, Akslen LA.

Breast Cancer Res Treat. 2012 Jun;133(2):501-10. doi: 10.1007/s10549-011-1785-7. Epub 2011 Sep 27.

PMID:
21947750
23.

Vascular proliferation is increased in basal-like breast cancer.

Nalwoga H, Arnes JB, Stefansson IM, Wabinga H, Foulkes WD, Akslen LA.

Breast Cancer Res Treat. 2011 Dec;130(3):1063-71. doi: 10.1007/s10549-011-1740-7. Epub 2011 Aug 28.

PMID:
21874512
24.

High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer.

Mauland KK, Trovik J, Wik E, Raeder MB, Njølstad TS, Stefansson IM, Oyan AM, Kalland KH, Bjørge T, Akslen LA, Salvesen HB.

Br J Cancer. 2011 Mar 15;104(6):921-6. doi: 10.1038/bjc.2011.46. Epub 2011 Feb 22.

25.

Gene expression patterns related to vascular invasion and aggressive features in endometrial cancer.

Mannelqvist M, Stefansson IM, Bredholt G, Hellem Bø T, Oyan AM, Jonassen I, Kalland KH, Salvesen HB, Akslen LA.

Am J Pathol. 2011 Feb;178(2):861-71. doi: 10.1016/j.ajpath.2010.10.040.

26.

Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer.

Trovik J, Wik E, Stefansson IM, Marcickiewicz J, Tingulstad S, Staff AC, Njolstad TS; MoMaTec Study Group, Vandenput I, Amant F, Akslen LA, Salvesen HB.

Clin Cancer Res. 2011 May 15;17(10):3368-77. doi: 10.1158/1078-0432.CCR-10-2412. Epub 2011 Jan 17.

27.

Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic setting.

Wik E, Trovik J, Iversen OE, Engelsen IB, Stefansson IM, Vestrheim LC, Haugland HK, Akslen LA, Salvesen HB.

Am J Obstet Gynecol. 2009 Dec;201(6):603.e1-7. doi: 10.1016/j.ajog.2009.07.029. Epub 2009 Oct 3.

PMID:
19800606
28.

Plasma calprotectin concentrations in women with endometrial carcinoma.

Ni Bhriain H, Trovik J, Wik E, Stefansson IM, Akslen LA, Salvesen HB, Staff AC.

Gynecol Oncol. 2009 Sep;114(3):491-5. doi: 10.1016/j.ygyno.2009.06.008. Epub 2009 Jul 3.

PMID:
19577278
29.

Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation.

Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, Stefansson IM, Raeder MB, Sos ML, Engelsen IB, Trovik J, Wik E, Greulich H, Bø TH, Jonassen I, Thomas RK, Zander T, Garraway LA, Oyan AM, Sellers WR, Kalland KH, Meyerson M, Akslen LA, Beroukhim R.

Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4834-9. doi: 10.1073/pnas.0806514106. Epub 2009 Mar 4.

30.

GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival.

Engelsen IB, Stefansson IM, Akslen LA, Salvesen HB.

Am J Obstet Gynecol. 2008 Nov;199(5):543.e1-7. doi: 10.1016/j.ajog.2008.04.043. Epub 2008 Jul 3.

PMID:
18599012
31.

Drug-sensitive FGFR2 mutations in endometrial carcinoma.

Dutt A, Salvesen HB, Chen TH, Ramos AH, Onofrio RC, Hatton C, Nicoletti R, Winckler W, Grewal R, Hanna M, Wyhs N, Ziaugra L, Richter DJ, Trovik J, Engelsen IB, Stefansson IM, Fennell T, Cibulskis K, Zody MC, Akslen LA, Gabriel S, Wong KK, Sellers WR, Meyerson M, Greulich H.

Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):8713-7. doi: 10.1073/pnas.0803379105. Epub 2008 Jun 13.

32.

Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma.

Engelsen IB, Mannelqvist M, Stefansson IM, Carter SL, Beroukhim R, Øyan AM, Otte AP, Kalland KH, Akslen LA, Salvesen HB.

Br J Cancer. 2008 May 20;98(10):1662-9. doi: 10.1038/sj.bjc.6604360. Epub 2008 May 13.

33.

HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas.

Engelsen IB, Stefansson IM, Beroukhim R, Sellers WR, Meyerson M, Akslen LA, Salvesen HB.

Int J Oncol. 2008 Feb;32(2):307-16.

PMID:
18202752
34.

Vascular proliferation is important for clinical progress of endometrial cancer.

Stefansson IM, Salvesen HB, Akslen LA.

Cancer Res. 2006 Mar 15;66(6):3303-9.

35.

Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer.

Collett K, Eide GE, Arnes J, Stefansson IM, Eide J, Braaten A, Aas T, Otte AP, Akslen LA.

Clin Cancer Res. 2006 Feb 15;12(4):1168-74.

36.

EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.

Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP, Akslen LA.

J Clin Oncol. 2006 Jan 10;24(2):268-73. Epub 2005 Dec 5.

PMID:
16330673
37.
38.

A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors.

Collett K, Stefansson IM, Eide J, Braaten A, Wang H, Eide GE, Thoresen SØ, Foulkes WD, Akslen LA.

Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1108-12.

39.
40.

Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer.

Stefansson IM, Salvesen HB, Akslen LA.

J Clin Oncol. 2004 Apr 1;22(7):1242-52.

PMID:
15051772
41.

The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer.

Foulkes WD, Brunet JS, Stefansson IM, Straume O, Chappuis PO, Bégin LR, Hamel N, Goffin JR, Wong N, Trudel M, Kapusta L, Porter P, Akslen LA.

Cancer Res. 2004 Feb 1;64(3):830-5.

42.

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

Foulkes WD, Stefansson IM, Chappuis PO, Bégin LR, Goffin JR, Wong N, Trudel M, Akslen LA.

J Natl Cancer Inst. 2003 Oct 1;95(19):1482-5.

PMID:
14519755

Supplemental Content

Loading ...
Support Center